# Canton Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/canton-biologics

- Industry: Outsourcing
- Headquarters: Guangzhou, China
- Website: www.cantonbio.com
- Total disclosed funding: $41M
- Latest round: Series C (Sep 13, 2023)
- Investors on record: 4

## About

Established in 2016 and based in Guangzhou, China, Canton Biologics operates as a biomolecule drug CDMO company that provides biomolecule drug development and manufacturing services, including monoclonal antibodies, duplex antibodies, fusion proteins and recombinant proteins. The company is headquartered in Guangzhou, and has R&D centers in Guangzhou and Germany as well as production centers in Foshan. It has a 12000m² commercialized production base and many awards, such as "National High-tech Enterprise" and Guangdong Province's "Pearl River Talent Program" innovation and entrepreneurship team. In February 2022, it acquired a Germany company - FyoniBio GmbH. In June 2023, the company was selected as one of “the Top 10 Most Growing CDMO Companies”. In September 2023, it raised over CNY 300 million in series C funding led by SDIC Venture Capital, with participation from Chnin Investment, Guangdong Technology Financial Group and Taipu Life Sciences Investment.

The company provides CMC development services, GMP manufacturing services and management systems services. CMC development services include molecular design, optimization and developmental assessment, cell line development and library construction, and upstream and downstream process development. GMP manufacturing services include toxicology, batch approval and clinical sample production, commercial production, quality control and test release, and aseptic filling. Management systems include project management, GMP manufacturing management, intellectual property management and drug registration management. In addition, it has related technology platforms, including cell line development platforms, process development platforms and analytical methods development platforms.

## Funding rounds

- Series C, Sep 13, 2023, $41M — Guangdong Technology Financial Group, SDIC Venture Capital, Chnin Investment, Taipu Life Sciences Investment

## Investors

- Guangdong Technology Financial Group (https://capitalatlas.ai/funds/guangdong-technology-financial-group) — Series C
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series C
- Chnin Investment (https://capitalatlas.ai/funds/chnin-investment) — Series C
- Taipu Life Sciences Investment — Series C